LXEO
Income statement / Annual
Last year (2024), Lexeo Therapeutics, Inc. Common Stock's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Lexeo Therapeutics, Inc. Common Stock's net income was -$98.33 M.
See Lexeo Therapeutics, Inc. Common Stock,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$0.00 |
$0.00 |
$654,000.00 |
$1.66 M |
$518,476.00 |
| Cost of Revenue |
$0.00
|
$1.84 M
|
$1.15 M
|
$13,405.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$1.84 M
|
-$491,000.00
|
$1.64 M
|
$518,476.00
|
| Gross Profit Ratio |
0
|
0
|
-0.75
|
0.99
|
1
|
| Research and Development Expenses |
$74.09 M
|
$53.13 M
|
$49.16 M
|
$45.12 M
|
$4.32 M
|
| General & Administrative Expenses |
$31.68 M
|
$15.38 M
|
$12.00 M
|
$7.17 M
|
$787,499.00
|
| Selling & Marketing Expenses |
$0.00
|
-$1.84 M
|
$0.00
|
-$13,379.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$31.68 M
|
$13.54 M
|
$12.00 M
|
$7.16 M
|
$787,499.00
|
| Other Expenses |
$0.00
|
$0.00
|
-$2,000.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$105.77 M
|
$66.67 M
|
$61.16 M
|
$52.29 M
|
$5.11 M
|
| Cost And Expenses |
$0.00
|
$68.51 M
|
$61.16 M
|
$52.29 M
|
$5.11 M
|
| Interest Income |
$7.56 M
|
$2.87 M
|
$1.33 M
|
$15,000.00
|
$0.00
|
| Interest Expense |
-$137,000.00
|
$205,000.00
|
$91,000.00
|
$0.00
|
$147,150.00
|
| Depreciation & Amortization |
$0.00
|
$1.84 M
|
$1.15 M
|
$13,000.00
|
$0.00
|
| EBITDA |
$0.00 |
-$66.67 M |
-$58.04 M |
-$50.62 M |
-$4.59 M |
| EBITDA Ratio |
0
|
0
|
-88.75
|
-30.55
|
-8.85
|
| Operating Income Ratio |
0
|
0
|
-92.52
|
-30.56
|
-8.85
|
| Total Other Income/Expenses Net |
$0.00
|
$2.12 M
|
$1.23 M
|
$15,000.00
|
-$565,000.00
|
| Income Before Tax |
-$98.33 M
|
-$66.39 M
|
-$59.28 M
|
-$50.62 M
|
-$5.15 M
|
| Income Before Tax Ratio |
0
|
0
|
-90.64
|
-30.55
|
-9.94
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$98.33 M
|
-$66.39 M
|
-$59.28 M
|
-$50.62 M
|
-$5.15 M
|
| Net Income Ratio |
0
|
0
|
-90.64
|
-30.55
|
-9.94
|
| EPS |
-3.09 |
-2.49 |
-2.36 |
-2.01 |
-0.2 |
| EPS Diluted |
-3.09 |
-2.49 |
-2.4 |
-2.01 |
-0.2 |
| Weighted Average Shares Out |
$31.79 M
|
$26.65 M
|
$25.17 M
|
$25.17 M
|
$25.17 M
|
| Weighted Average Shares Out Diluted |
$31.79 M
|
$26.65 M
|
$25.17 M
|
$25.17 M
|
$25.17 M
|
| Link |
|
|
|
|
|
